Bellerophon Therapeutics Doses Last Patient in Phase 3 Lung Disease Study
Bellerophon Therapeutics (Nasdaq: BLPH) has announced that the last patient has completed blinded treatment in the company’s ongoing Phase 3 REBUILD study.
Bellerophon’s Phase 3 study is evaluating INOpulse®, a proprietary pulsatile nitric oxide delivery system, for the treatment of fibrotic interstitial lung disease (fILD).
The company’s share price rose 20% following the news.
Highlights
Bellerophon expects to deliver topline results from the study in mid-2023.
The REBUILD study is a Phase 3, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of pulsed inhaled nitric oxide (iNO) in patients at risk for pulmonary hypertension associated with pulmonary fibrosis on long-term oxygen therapy.
A total of 145 fILD patients were enrolled and treated with either INOpulse at a dose of iNO45 or placebo.
If approved, INOpulse would become the first therapy to treat a broad fILD population, including patients at low-, intermediate- and high-risk pulmonary hypertension.
About Bellerophon Therapeutics
Bellerophon Therapeutics is a clinical-stage biotherapeutics company developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company is currently developing multiple product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery system.
